Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines

20161005-ov-vancouver-vacv-antibody-poster-final-us

Published 5 October 2016
Categorized as 2016, Press release

Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials

20160905 – H1 update – EN – V10

Published 5 September 2016
Categorized as 2016, Press release

Transgene Announces Participation at Upcoming Investor Events

20160901 – Next investor events – EN

Published 1 September 2016
Categorized as 2016, Press release

Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee

20160721 – Safety TG1050 EN Vdef

Published 21 July 2016
Categorized as 2016, Press release, TG1050

Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy

20160531 – ASCO_Poster_PR_V2_clean

Published 31 May 2016
Categorized as 2016, Pexa-Vec, Press release

Composition of the Board of Directors and Statutory Auditors

20160525 – nomination Mr Beret – us

Published 25 May 2016
Categorized as 2016, Press release

Transgene Reports First Quarter 2016 Business Update

20160421 PR VEN Q1 2016 – V4 clean

Published 21 April 2016
Categorized as 2016, Press release

Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody (poster)

20160419 AACR Poster PR Final

Published 19 April 2016
Categorized as 2016, Press release

Transgene Hires Two Senior Pharmaceutical Industry Executives to Join Leadership Team

20160317 Appointments PR Final

Published 17 March 2016
Categorized as 2016, Press release

Transgene Reports 2015 Financial Results and Provides Outlook for 2016 (webcast)

20160309 FY 2015 results version FINALE

Published 8 March 2016
Categorized as 2016, Press release

Posts pagination

Newer posts Page 1 … Page 30 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu